Cargando…

A 48-week randomized phase 2b study evaluating cenicriviroc versus efavirenz in treatment-naive HIV-infected adults with C-C chemokine receptor type 5-tropic virus

OBJECTIVE: To compare the efficacy, safety, and anti-inflammatory effects of cenicriviroc (CVC), an oral, once-daily C-C chemokine receptor types 5 and 2 antagonist, with those of efavirenz (EFV) in treatment-naive, HIV-1-infected adults. DESIGN: A 48-week, randomized, double-blind, double-dummy pha...

Descripción completa

Detalles Bibliográficos
Autores principales:	Thompson, Melanie, Saag, Michael, DeJesus, Edwin, Gathe, Joseph, Lalezari, Jay, Landay, Alan L., Cade, Jerry, Enejosa, Jeffrey, Lefebvre, Eric, Feinberg, Judith
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2016
Materias:	Clinical Science
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4794136/ https://www.ncbi.nlm.nih.gov/pubmed/26636929 http://dx.doi.org/10.1097/QAD.0000000000000988

Ejemplares similares

Efficacy and safety of maraviroc vs. efavirenz in treatment-naive patients with HIV-1: 5-year findings
por: Cooper, David A., et al.
Publicado: (2014)

SUPPORT: 48-week results of fosamprenavir/ritonavir vs efavirenz with abacavir/lamivudine in under-represented, antiretroviral-naïve patients
por: Kumar, P, et al.
Publicado: (2010)

The chemokine receptor antagonist cenicriviroc inhibits the replication of SARS-CoV-2 in vitro
por: Okamoto, Mika, et al.
Publicado: (2020)

APOBEC3G/3A Expression in Human Immunodeficiency Virus Type 1-Infected Individuals Following Initiation of Antiretroviral Therapy Containing Cenicriviroc or Efavirenz
por: Covino, Daniela A., et al.
Publicado: (2018)

Rationale of using the dual chemokine receptor CCR2/CCR5 inhibitor cenicriviroc for the treatment of COVID-19
por: Files, Daniel Clark, et al.
Publicado: (2022)

Efficacy and Safety of Cenicriviroc in Patients With Primary Sclerosing Cholangitis: PERSEUS Study
por: Eksteen, Bertus, et al.
Publicado: (2020)

Role of cenicriviroc in the management of nonalcoholic fatty liver disease
por: Neokosmidis, Georgios, et al.
Publicado: (2018)

Cenicriviroc blocks HIV entry but does not lead to redistribution of HIV into extracellular space like maraviroc
por: Kramer, Victor, et al.
Publicado: (2014)

A randomized, placebo‐controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis
por: Friedman, Scott L., et al.
Publicado: (2018)

Cenicriviroc, a Novel CCR5 (R5) and CCR2 Antagonist, Shows In Vitro Activity against R5 Tropic HIV-2 Clinical Isolates
por: Visseaux, Benoit, et al.
Publicado: (2015)

Pharmacokinetics, Safety, and CCR2/CCR5 Antagonist Activity of Cenicriviroc in Participants With Mild or Moderate Hepatic Impairment
por: Lefebvre, E, et al.
Publicado: (2016)

Evaluation of cardiovascular biomarkers in a randomized trial of fosamprenavir/ritonavir vs. efavirenz with abacavir/lamivudine in underrepresented, antiretroviral-naïve, HIV-infected patients (SUPPORT): 96-week results
por: Kumar, Princy, et al.
Publicado: (2013)

Efficacy of evogliptin and cenicriviroc against nonalcoholic steatohepatitis in mice: a comparative study
por: Wang, Zheng, et al.
Publicado: (2019)

Differential impact of the dual CCR2/CCR5 inhibitor cenicriviroc on migration of monocyte and lymphocyte subsets in acute liver injury
por: Puengel, Tobias, et al.
Publicado: (2017)

Antifibrotic Effects of the Dual CCR2/CCR5 Antagonist Cenicriviroc in Animal Models of Liver and Kidney Fibrosis
por: Lefebvre, Eric, et al.
Publicado: (2016)

Prolonged cenicriviroc therapy reduces hepatic fibrosis despite steatohepatitis in a diet‐induced mouse model of nonalcoholic steatohepatitis
por: Kruger, Annie J., et al.
Publicado: (2018)

The dual CCR2/CCR5 chemokine receptor antagonist Cenicriviroc reduces macrophage infiltration and disease severity in Duchenne muscular dystrophy (Dmd(mdx-4Cv)) mice
por: Liang, Feng, et al.
Publicado: (2018)

Comparative Changes of Lipid Levels in Treatment-Naive, HIV-1-Infected Adults Treated with Dolutegravir vs. Efavirenz, Raltegravir, and Ritonavir-Boosted Darunavir-Based Regimens Over 48 Weeks
por: Quercia, Romina, et al.
Publicado: (2015)

Poor Efficacy and Tolerability of Stavudine, Didanosine, and Efavirenz-based Regimen in Treatment-Naive Patients in Senegal
por: Canestri, Anna, et al.
Publicado: (2007)

Evaluating the Therapeutic Potential of Cenicriviroc in the Treatment of Nonalcoholic Steatohepatitis with Fibrosis: A Brief Report on Emerging Data
por: Diaz Soto, Maria Paula, et al.
Publicado: (2020)

Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate is Non-inferior to Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment-naive Adults With Human Immunodeficiency Virus–1 Infection: Week 48 Results of the DRIVE-AHEAD Trial
por: Orkin, Chloe, et al.
Publicado: (2019)

Nevirapine and Efavirenz Elicit Different Changes in Lipid Profiles in Antiretroviral- Therapy-Naive Patients Infected with HIV-1
por: van Leth, Frank, et al.
Publicado: (2004)

Single-tablet regimen is associated with reduced efavirenz withdrawal in antiretroviral naïve or switching for simplification HIV-infected patients
por: Fabbiani, M, et al.
Publicado: (2012)

Pharmacodynamics of efavirenz 400 mg in treatment-naïve Chinese HIV-infected patients in a prospective cohort study
por: Xu, Ling, et al.
Publicado: (2021)

Efavirenz-mediated induction of omeprazole metabolism is CYP2C19 genotype-dependent
por: Michaud, Veronique, et al.
Publicado: (2013)

Efavirenz and neuropsychiatric effects
por: Dheda, Mukesh
Publicado: (2017)

Efavirenz, dysrhythmia and HIV
por: Mungmunpuntipantip, Rujittika, et al.
Publicado: (2021)

Tropifexor plus cenicriviroc combination versus monotherapy in nonalcoholic steatohepatitis: Results from the phase 2b TANDEM study
por: Anstee, Quentin M., et al.
Publicado: (2023)

Switching efavirenz to rilpivirine in virologically suppressed adolescents with HIV: a multi‐centre 48‐week efficacy and safety study in Thailand
por: Phongsamart, Wanatpreeya, et al.
Publicado: (2022)

C-C Chemokine Receptor 7 in Cancer
por: Bill, Colin A., et al.
Publicado: (2022)

Identification of C-C Chemokine Receptor 1 (CCR1) as the Monocyte Hemofiltrate C-C Chemokine (HCC)-1 Receptor
por: Tsou, Chia-Lin, et al.
Publicado: (1998)

Correction: Nevirapine and Efavirenz Elicit Different Changes in Lipid Profiles in Antiretroviral-Therapy-Naive Patients Infected with HIV-1
Publicado: (2004)

The SENSE trial: etravirine shows lower prevalence and severity of neuropsychiatric adverse events compared to efavirenz in treatment-naïve patients
por: Stellbrink, HJ, et al.
Publicado: (2010)

Single tablet regimens are associated with reduced Efavirenz withdrawal in antiretroviral therapy naïve or switching for simplification HIV-infected patients
por: Fabbiani, Massimiliano, et al.
Publicado: (2014)

Incidence of neuropsychiatric side effects of efavirenz in HIV-positive treatment-naïve patients in public-sector clinics in the Eastern Cape
por: Gaida, Razia, et al.
Publicado: (2016)

Durability of Efavirenz Compared With Boosted Protease Inhibitor-Based Regimens in Antiretroviral-Naïve Patients in the Caribbean and Central and South America
por: Caro-Vega, Yanink, et al.
Publicado: (2018)

Correction to: Pharmacodynamics of efavirenz 400 mg in treatment-naïve Chinese HIV-infected patients in a prospective cohort study
por: Xu, Ling, et al.
Publicado: (2021)

Promising Modulatory Effects of Cenicriviroc on the Progression of Mouse Colorectal Cancer through Inhibition of CCR2_CCL2 Signaling Pathway
por: Eslami, Mina, et al.
Publicado: (2023)

Potentials of C‐C motif chemokine 2–C‐C chemokine receptor type 2 blockers including propagermanium as anticancer agents
por: Yumimoto, Kanae, et al.
Publicado: (2019)

The Critical Role of Chemokine (C–C Motif) Receptor 2-Positive Monocytes in Autoimmune Cholangitis
por: Reuveni, Debby, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_g4muctc101pc2n9ggqoou510m5